The global clinical trial technology market is projected to reach USD 22.7 billion by 2030, expanding at a compound annual growth rate (CAGR) of 8.3%. Within this, AI-enabled patient recruitment ...

CARDAMYST nasal spray is a novel and rapid-acting calcium channel blocker delivered when needed to treat often highly symptomatic and unpredictable episodes of PSVT. With CARDAMYST, adults with PSVT ...

Genesis shares interested parties’ focus on patients, residents and staff, and the importance of safeguarding access to high-quality post-acute care in the communities served by the more than 170 ...

As per previous communication, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had informed Anavex about a negative trend-vote following its oral examination in ...

The aggregate gross proceeds to the Company from the offering were approximately $8.0 million before deducting the placement agent's fees and other offering expenses payable by the Company. The ...

CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to ...

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of December 2025, which is payable ...

In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: ...

Subject to TSX Venture Exchange (“ TSXV ”) approval, NurExone has engaged Russo Partners LLC, a New York–based strategic communications firm, (“ Russo ”) for an initial consulting project for up to ...

We are in the early stages of our growth strategy and our public offering provided us with the next step in expanding our base of stakeholders to help us deliver on our desire to become a leader in ...

TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on the “Investors” page on its ...

At September 30, 2025, Edesa had cash and cash equivalents of $10.8 million and working capital of $10.4 million. Subsequent to the fiscal year end, the company received $3.4 million in net proceeds, ...